| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | J&J says 2026 sales could top $100 billion | ||
| Do | Amazon joins the AI health assistant movement | ||
| Do | NICE backs Roche lupus drug that supports kidney function | ||
| Do | US checks out of WHO, leaving its bill unsettled | ||
| Do | 11 high-impact drugs to look out for in 2026 | ||
| Mi | EU approves Otsuka's long-acting HAE drug Dawnzera | ||
| Mi | Hopstem maps course to bring stem cell stroke therapy to US | ||
| Mi | ImmunityBio rises as route opens to broader Anktiva label | ||
| Mi | Call goes out for type 1 diabetes screening in UK | ||
| Mi | Data builds behind Moderna's skin cancer vaccine | ||
| Di | J&J bets on Isomorphic for AI-powered drug hunt | ||
| Di | ViiV ownership shifts as Pfizer sells its stake | ||
| Di | Agomab and Spyglass push the IPO button | ||
| Di | AstraZeneca pays $630m to get full control of AbelZeta CAR-T | ||
| Di | GSK reaches $2.2bn deal to buy food allergy biotech RAPT | ||
| Mo | Sun Pharma says talk of $10bn Organon bid is 'speculative' | ||
| Mo | EU starts review of first-line Enhertu for breast cancer | ||
| Mo | Could Alzheimer's be predicted with a finger-prick test? | ||
| Mo | NICE relents, ending postcode access to prostate cancer drug | ||
| Mo | 'Skinny' generic Vascepa label case reaches US Supreme Court | ||
| 16.01. | Wegovy pill shows strong early uptake, as rival looms | ||
| 16.01. | Sanofi linked to takeover bid for Ocular Therapeutix | ||
| 16.01. | Ocugen shares fall, despite positive eye disorder trial | ||
| 16.01. | Autonomous AI can spot cognitive decline in medical notes | ||
| 16.01. | Trump's affordability plan arrives, built around MFN pricing |